These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 17692108)

  • 21. Reversibility of androgen deprivation therapy in patients with prostate cancer.
    Fridmans A; Chertin B; Koulikov D; Lindenberg T; Gelber H; Leiter C; Farkas A; Spitz IM
    J Urol; 2005 Mar; 173(3):784-9. PubMed ID: 15711270
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of bicalutamide therapy on prolactin response to L-dopa in metastatic prostate cancer patients.
    Lissoni P; Malugani F; Casu M; Bukovec R; Egardi R; Bordin V; Fumagalli E; Mengo S; Gardani G
    Neuro Endocrinol Lett; 2002 Feb; 23(1):61-3. PubMed ID: 11880864
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A phase II study of nilutamide in men with prostate cancer after the failure of flutamide or bicalutamide therapy.
    Davis NB; Ryan CW; Stadler WM; Vogelzang NJ
    BJU Int; 2005 Oct; 96(6):787-90. PubMed ID: 16153201
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Personal experience with determination of NT-proBNP in clinical practice].
    Stejskal D; Oral I; Lacnák B; Juráková R; Horalík D; Adamovská S; Prosková J; Hrabovská I; Ozanová G
    Vnitr Lek; 2003 Feb; 49(2):121-6. PubMed ID: 12728579
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Radiation dose predicts for biochemical control in intermediate-risk prostate cancer patients treated with low-dose-rate brachytherapy.
    Ho AY; Burri RJ; Cesaretti JA; Stone NN; Stock RG
    Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):16-22. PubMed ID: 19289266
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Degarelix versus goserelin plus bicalutamide therapy for lower urinary tract symptom relief, prostate volume reduction and quality of life improvement in men with prostate cancer: a systematic review and meta-analysis.
    Cui Y; Zong H; Yan H; Li N; Zhang Y
    Urol Int; 2014; 93(2):152-9. PubMed ID: 24603064
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of Androgen Deprivation Therapy on Volume Reduction and Lower Urinary Tract Symptoms in Patients with Prostate Cancer.
    Washino S; Hirai M; Saito K; Kobayashi Y; Arai Y; Miyagawa T
    Low Urin Tract Symptoms; 2018 Jan; 10(1):57-63. PubMed ID: 27943566
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Report of a multicenter Canadian phase III randomized trial of 3 months vs. 8 months neoadjuvant androgen deprivation before standard-dose radiotherapy for clinically localized prostate cancer.
    Crook J; Ludgate C; Malone S; Lim J; Perry G; Eapen L; Bowen J; Robertson S; Lockwood G
    Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):15-23. PubMed ID: 15337535
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Degarelix versus goserelin (+ antiandrogen flare protection) in the relief of lower urinary tract symptoms secondary to prostate cancer: results from a phase IIIb study (NCT00831233).
    Anderson J; Al-Ali G; Wirth M; Gual JB; Gomez Veiga F; Colli E; van der Meulen E; Persson BE
    Urol Int; 2013; 90(3):321-8. PubMed ID: 23258223
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
    Suzuki H; Okihara K; Miyake H; Fujisawa M; Miyoshi S; Matsumoto T; Fujii M; Takihana Y; Usui T; Matsuda T; Ozono S; Kumon H; Ichikawa T; Miki T;
    J Urol; 2008 Sep; 180(3):921-7. PubMed ID: 18635218
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Partial androgen suppression consequent to increased secretion of adrenal androgens in a patient with prostate cancer treated with long-acting GnRH agonists.
    Spitz IM; Chertin B; Fridmans A; Farkas A; Belanger A; Hartman H; Labrie F
    Prostate Cancer Prostatic Dis; 2009; 12(1):100-3. PubMed ID: 18574491
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Associations among androgens, estrogens, and natriuretic peptides in young women: observations from the Dallas Heart Study.
    Chang AY; Abdullah SM; Jain T; Stanek HG; Das SR; McGuire DK; Auchus RJ; de Lemos JA
    J Am Coll Cardiol; 2007 Jan; 49(1):109-16. PubMed ID: 17207730
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Salvage therapy with bicalutamide 150 mg in nonmetastatic castration-resistant prostate cancer.
    Lodde M; Lacombe L; Fradet Y
    Urology; 2010 Nov; 76(5):1189-93. PubMed ID: 20303155
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The patient's choice of androgen-deprivation therapy in locally advanced prostate cancer: bicalutamide, a gonadotrophin-releasing hormone analogue or orchidectomy.
    Nyman CR; Andersen JT; Lodding P; Sandin T; Varenhorst E
    BJU Int; 2005 Nov; 96(7):1014-8. PubMed ID: 16225519
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Exploratory study of drug plasma levels during bicalutamide 150 mg therapy co-administered with tamoxifen or anastrozole for prophylaxis of gynecomastia and breast pain in men with prostate cancer.
    Boccardo F; Rubagotti A; Conti G; Potenzoni D; Manganelli A; Del Monaco D
    Cancer Chemother Pharmacol; 2005 Oct; 56(4):415-20. PubMed ID: 15838655
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of nonsteroidal antiandrogen monotherapy versus castration therapy on neuroendocrine differentiation in prostate carcinoma.
    Sciarra A; Di Silverio F
    Urology; 2004 Mar; 63(3):523-7. PubMed ID: 15028450
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Goserelin and bicalutamide treatments alter the expression of microRNAs in the prostate.
    Lehmusvaara S; Erkkilä T; Urbanucci A; Jalava S; Seppälä J; Kaipia A; Kujala P; Lähdesmäki H; Tammela TL; Visakorpi T
    Prostate; 2013 Jan; 73(1):101-12. PubMed ID: 22674191
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Monitoring of erection function in patients with prostatic carcinoma treated with Casodex].
    Migliari R; Muscas G; Melis M; Garau M; Sorgia M; Scarpa RM; Usai E
    Arch Ital Urol Nefrol Androl; 1991 Mar; 63(1):155-61. PubMed ID: 1830408
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Duration of androgen suppression in the treatment of prostate cancer.
    Bolla M; de Reijke TM; Van Tienhoven G; Van den Bergh AC; Oddens J; Poortmans PM; Gez E; Kil P; Akdas A; Soete G; Kariakine O; van der Steen-Banasik EM; Musat E; Piérart M; Mauer ME; Collette L;
    N Engl J Med; 2009 Jun; 360(24):2516-27. PubMed ID: 19516032
    [TBL] [Abstract][Full Text] [Related]  

  • 40. N-terminal pro-brain natriuretic protein levels in takotsubo cardiomyopathy.
    Nguyen TH; Neil CJ; Sverdlov AL; Mahadavan G; Chirkov YY; Kucia AM; Stansborough J; Beltrame JF; Selvanayagam JB; Zeitz CJ; Struthers AD; Frenneaux MP; Horowitz JD
    Am J Cardiol; 2011 Nov; 108(9):1316-21. PubMed ID: 21871590
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.